Nationwide survey on complementary and alternative medicine in cancer patients in Japan
Nationwide survey on complementary and alternative medicine in cancer patients in Japan
复制标题
DOI：
10.1200/jco.2005.04.126
复制
发表时间：
2005-04-20
影响因子：
45.3
通讯作者：
Takashima, S
中科院分区：
文献类型：
--
作者：
Hyodo, I;Amano, N;Takashima, S
目的确定日本癌症患者使用补充和替代医学 (CAM) 的流行情况，并比较 CAM 用户和 CAM 非用户的特征。患者和方法向在 16 个癌症中心和 40 个姑息治疗单位接受治疗的 6,607 名患者发放了癌症 CAM 调查问卷和医院焦虑和抑郁量表。结果共有 3,461 份有效答复，答复率为 52.4%。癌症患者中 CAM 的使用率为 44.6%（3,100 人中的 1,382 人），良性肿瘤非癌症患者中的 CAM 使用率为 25.5%（361 人中的 92 人）。多元 Logistic 回归分析确定，化疗史、机构（姑息治疗单位）、高等教育、癌症诊断后生活观的改变、原发癌症部位和年龄与癌症患者 CAM 的使用密切相关。大多数患有癌症的 CAM 用户 (96.2%) 使用蘑菇、草药和鲨鱼软骨等产品。大多数使用 CAM 的动机是家人或朋友的推荐（77.7%），而不是个人选择（23.3%）。尽管所有患有癌症的 CAM 用户都同时接受了常规癌症治疗，但仍有 24.3% 的患者体验到了积极效果。 5.3%的癌症患者报告了不良反应。 57.3% 的癌症用户在没有充分信息的情况下使用 CAM 产品，60.7% 的用户在没有咨询医生的情况下使用 CAM 产品。结论 这项调查显示，癌症患者在没有充分信息或咨询医生的情况下使用 CAM 产品的比例很高。肿瘤学家不应因为缺乏经过证实的功效和安全性而忽视患者使用的 CAM 产品。
PurposeTo determine the prevalence of use of complementary and alternative medicine (CAM) by patients with cancer in Japan, and to compare the characteristics of CAM users and CAM nonusers.Patients and MethodsA questionnaire on cancer CAM and the Hospital Anxiety and Depression Scale were delivered to 6,607 patients who were treated in 16 cancer centers and 40 palliative care units.ResultsThere were 3,461 available replies for a response rate of 52.4%. The prevalence of CAM use was 44.6% (1,382 of 3,100) in cancer patients and 25.5% (92 of 361) in noncancer patients with benign tumors. Multiple logistic regression analysis determined that history of chemotherapy, institute (palliative care units), higher education, an altered outlook on life after cancer diagnosis, primary cancer site, and younger age were strongly associated with CAM use in cancer patients. Most of the CAM users with cancer (96.2%) used products such as mushrooms, herbs, and shark cartilage. The motivation for most CAM use was recommendation from family members or friends (77.7%) rather than personal choice (23.3%). Positive effects were experienced by 24.3% of CAM users with cancer, although all of them received conventional cancer therapy concurrently. Adverse reactions were reported by 5.3% of cancer patients. CAM products were used without sufficient information by 57.3% of users with cancer and without a consultation with a doctor by 60.7% of users.ConclusionThis survey revealed a high prevalence of CAM use among cancer patients, without sufficient information or consultation with their physicians. Oncologists should not ignore the CAM products used by their patients because of a lack of proven efficacy and safety.